Latest:

Fat Pitch Financials

Special situation stocks and value investing

Stock Quote

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Albireo Pharma Inc (NQ: ALBO )

32.90 USD +0.30 (+0.92%)
Official Closing Price Updated: 5:02 PM EDT, Apr 19, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All news about Albireo Pharma Inc

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Albireo Expands Leadership with Joan Connolly as Chief Technology Officer
From GlobeNewswire News Releases
We Did The Math LABU Can Go To $118
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
Albireo to Participate in the Needham 20th Annual Virtual Healthcare Conference
From GlobeNewswire News Releases
Albireo Pharma (ALBO) Shares Cross Below 200 DMA
In trading on Monday, shares of Albireo Pharma Inc (ALBO) crossed below their 200 day moving average of $33.59, changing hands as low as $33.54 per share. Albireo Pharma Inc shares are currently... 
Tags Stocks
From Market News Video
Albireo Announces First Patients Dosed in Two New Studies
From GlobeNewswire News Releases
How The Parts Add Up: LABU Targets $125
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
Albireo Spotlights Global Patient Communities on Rare Disease Day
From GlobeNewswire News Releases
Albireo Pharma, Inc. (ALBO) Q4 2020 Earnings Call Transcript
ALBO earnings call for the period ending December 31, 2020. 
Tags ALBO Market News
From Motley Fool
The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ... 
Tags GNMK Guidance IOVA
From Benzinga
Albireo Reports Q4 and Year-End 2020 Financial Results and Business Update
From GlobeNewswire News Releases
Albireo to Participate in Cowen and H.C. Wainwright Global Investor Conferences
From GlobeNewswire News Releases
The Week Ahead In Biotech: J&J Vaccine Adcom Meeting, Sarepta FDA Decision And Plenty Of Earnings
Biotech stocks pulled back along with the broader market in the holiday-shortened week ended Feb 19. Earnings news flow was light before ... 
Tags MGNX CLBS TBPH
From Benzinga
Albireo to Report Q4 and Year-End 2020 Financial Results on February 25
Conference call and webcast to be held at 10:00 a.m. ET 
From GlobeNewswire News Releases
Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From GlobeNewswire News Releases
Albireo Presents Odevixibat Commercialization Road to $1 Billion
From GlobeNewswire News Releases
Albireo Announces U.S. FDA Acceptance of New Drug Application for Odevixibat
From GlobeNewswire News Releases
Albireo Recognizes International Alagille Syndrome Awareness Day 2021
Albireo supports the Alagille syndrome community to advocate for more education and new treatment advances for rare cholestatic liver diseases 
From GlobeNewswire News Releases
Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From GlobeNewswire News Releases
Albireo to Host Virtual Investor Commercial Day 2021
From GlobeNewswire News Releases
Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From GlobeNewswire News Releases
Albireo to Participate in H.C. Wainwright BioConnect and LifeSci Advisors Investor Conferences
From GlobeNewswire News Releases
Albireo Initiates Global Phase 3 Clinical Trial of Odevixibat in Alagille Syndrome
From GlobeNewswire News Releases
Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From GlobeNewswire News Releases
Albireo Submits for U.S. FDA and EMA Product Approval of Once-Daily Odevixibat for PFIC
From GlobeNewswire News Releases
How The Parts Add Up: DWAS Headed For $77
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
The Week Ahead In Biotech: The Vaccine Updates, Drug Presentations, And FDA Decisions That Will Move The Markets
Biotech stocks advanced in the week ended Nov. 13 amid a vaccine news flow-induced rally that also lifted the broader market. The ... 
Tags EIGR MYL SUPN
From Benzinga
New Phase 3 Data at AASLD Show Durable Response to Odevixibat in a Rare Pediatric Liver Disease
From GlobeNewswire News Releases
Albireo to Participate in Jefferies and Piper Sandler Virtual Investor Conferences
From GlobeNewswire News Releases
Albireo Reports Q3 2020 Financial Results and Provides Business Update
From GlobeNewswire News Releases
Albireo’s Odevixibat PFIC Phase 3 Results Accepted for AASLD Late-Breakers
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.